Ligand Pharmaceuticals Statistics
Total Valuation
SBREF has a market cap or net worth of 487.82 million. The enterprise value is 440.63 million.
| Market Cap | 487.82M |
| Enterprise Value | 440.63M |
Important Dates
The last earnings date was Thursday, July 31, 2025.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | Apr 17, 2025 |
Share Statistics
| Current Share Class | 248.03M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.15% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 203.25M |
Valuation Ratios
The trailing PE ratio is 8.95 and the forward PE ratio is 9.49.
| PE Ratio | 8.95 |
| Forward PE | 9.49 |
| PS Ratio | 1.65 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 3.95 |
| P/FCF Ratio | 11.03 |
| P/OCF Ratio | 11.02 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.24, with an EV/FCF ratio of 9.96.
| EV / Earnings | 8.09 |
| EV / Sales | 1.55 |
| EV / EBITDA | 6.24 |
| EV / EBIT | 6.26 |
| EV / FCF | 9.96 |
Financial Position
The company has a current ratio of 0.50
| Current Ratio | 0.50 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 16.39% and return on invested capital (ROIC) is 13.69%.
| Return on Equity (ROE) | 16.39% |
| Return on Assets (ROA) | 4.90% |
| Return on Invested Capital (ROIC) | 13.69% |
| Return on Capital Employed (ROCE) | 20.90% |
| Revenue Per Employee | 1.77M |
| Profits Per Employee | 326,302 |
| Employee Count | 167 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SBREF has paid 19.24 million in taxes.
| Income Tax | 19.24M |
| Effective Tax Rate | 26.09% |
Stock Price Statistics
| Beta (5Y) | 0.26 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 8,378 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SBREF had revenue of 294.95 million and earned 54.49 million in profits. Earnings per share was 0.22.
| Revenue | 294.95M |
| Gross Profit | 73.29M |
| Operating Income | 72.84M |
| Pretax Income | 73.73M |
| Net Income | 54.49M |
| EBITDA | 73.05M |
| EBIT | 72.84M |
| Earnings Per Share (EPS) | 0.22 |
Balance Sheet
The company has 48.81 million in cash and n/a in debt, giving a net cash position of 48.81 million.
| Cash & Cash Equivalents | 48.81M |
| Total Debt | n/a |
| Net Cash | 48.81M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 337.50M |
| Book Value Per Share | 1.36 |
| Working Capital | -294.59M |
Cash Flow
In the last 12 months, operating cash flow was 44.25 million and capital expenditures -17,811, giving a free cash flow of 44.23 million.
| Operating Cash Flow | 44.25M |
| Capital Expenditures | -17,811 |
| Free Cash Flow | 44.23M |
| FCF Per Share | n/a |
Margins
Gross margin is 24.85%, with operating and profit margins of 24.70% and 18.48%.
| Gross Margin | 24.85% |
| Operating Margin | 24.70% |
| Pretax Margin | 25.00% |
| Profit Margin | 18.48% |
| EBITDA Margin | 24.77% |
| EBIT Margin | 24.70% |
| FCF Margin | 15.00% |
Dividends & Yields
This stock pays an annual dividend of 0.17, which amounts to a dividend yield of 8.76%.
| Dividend Per Share | 0.17 |
| Dividend Yield | 8.76% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 81.00% |
| Buyback Yield | -0.15% |
| Shareholder Yield | 8.61% |
| Earnings Yield | 11.17% |
| FCF Yield | 9.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |